August 08, 2018 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Revenues of $1,593,000 USD. Previously, on May 10, 2018, La Jolla Pharmaceutical Co. reported Revenues of $809,000 USD. This represents a change of 96.91% in Revenues.
<a href="https://fintel.io/fg/us/ljpc/Revenues"><img src="https://images.fintel.io/us-ljpc-revenues.png" alt="LJPC / La Jolla Pharmaceutical Co. Revenues"><a>
Related News Stories
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-4)